Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iguratimod plus NSAID versus placebo plus NSAID for active ankylosing spondylitis or axial spondyloarthritis
ChiCTR2000029112Phase 3Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Sep 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of iguratimod and celecoxib in ankylosing spondylitis (AS) and axial spondyloarthritis (axSpA) (2 arms), sponsored by Ruijin Hospital. Primary endpoints: NSAID index over 28 weeks of therapy and Number of participants achieving ASAS 20 at week 28. Started Sep 2019; status: recruiting.
02
Drugs
iguratimodcelecoxib
03
Conditions
ankylosing spondylitis (AS)axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on ChiCTR2000029112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000029112.